阿利马特拉韦每月一次口服用于HIV暴露低风险成人的随机双盲安慰剂对照研究
各剂量组不良事件发生率与安慰剂相当,药代动力学参数呈剂量比例关系并支持每月一次给药。结论认为其安全性和药代动力学特征支持继续开发为口服每月一次暴露前预防药物。
要点
- 阿利马特拉韦3、6、12 mg每4周一次口服的安全性与安慰剂相当。
- 药代动力学参数呈剂量比例,支持每月一次给药间隔。
- 因不良事件停药率阿利马特拉韦组为1.0%,安慰剂组为4.1%。
核心结论
- 阿利马特拉韦及其三磷酸代谢物的安全性、耐受性和药代动力学特征支持继续开发为口服每月一次HIV暴露前预防药物。
研究设计与样本
- 双盲、安慰剂对照研究,纳入18-65岁HIV-1暴露可能性低的成人,按2:2:2:1随机接受阿利马特拉韦3、6、12 mg或安慰剂每4周一次口服共6剂。
主要发现
- 不良事件发生率:阿利马特拉韦3 mg组61.4%(62/101)、6 mg组68.3%(69/101)、12 mg组66.7%(66/99)、安慰剂组63.3%(31/49)。
- 因不良事件终止研究干预的比例:阿利马特拉韦组1.0%(3/301),安慰剂组4.1%(2/49)。
- 阿利马特拉韦血浆药代动力学参数及外周血单核细胞中阿利马特拉韦三磷酸参数呈剂量比例,支持每月一次给药间隔。
临床怎么用
- 该研究为早期安全性及药代动力学评估,尚未在HIV暴露风险人群中进行有效性验证,目前不应用于临床预防实践。
局限性
- 研究对象为HIV-1暴露可能性低的成人,未评估暴露前预防的有效性。
- 药代动力学亚组分析仅从每个阿利马特拉韦剂量组约20名参与者中采集外周血单核细胞样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-acting oral options for human immunodeficiency virus-1 (HIV-1) pre-exposure prophylaxis are needed to address challenges with adherence to once-daily regimens. Alimatravir is an oral nucleoside reverse transcriptase translocation inhibitor with pharmacokinetic properties supporting once-monthly dosing. METHODS: In this double-blind, placebo-controlled study, adults aged 18-65 years with low likelihood of HIV-1 exposure were randomly assigned 2:2:2:1 to receive 6 oral doses of alimatravir (3, 6, or 12 mg) or placebo once every 4 weeks. The primary outcome was the proportion of participants with adverse events through 8 weeks after the last dose, assessed in participants who received at least one dose of study intervention. Additional outcomes were the pharmacokinetics of alimatravir in plasma (all participants) and alimatravir-triphosphate in peripheral blood mononuclear cells (∼ 20 participants from each alimatravir dose group). RESULTS: Three hundred fifty participants were included in the analyses (median age 28 years; 58% female): 301 received alimatravir 3 mg (n = 101), 6 mg (n = 101), or 12 mg (n = 99) and 49 received placebo. Adverse event rates were comparable for alimatravir 3 mg (61.4% [62/101]), 6 mg (68.3% [69/101]), 12 mg (66.7% [66/99]), and placebo (63.3% [31/49]). Study intervention was discontinued because of an adverse event in 1.0% (3/301) of participants who received alimatravir and 4.1% (2/49) who received placebo. Pharmacokinetic parameters for alimatravir and alimatravir-triphosphate were dose-proportional and support a once-monthly dosing interval. CONCLUSIONS: The favorable safety, tolerability, and pharmacokinetics of alimatravir and alimatravir-triphosphate support continued development of alimatravir as oral monthly pre-exposure prophylaxis. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier NCT06045507; https://www.clinicaltrials.gov/search.
引用
- Mayer KH, Kotze P, Lombaard J, et al. Alimatravir Oral Once Monthly in Adults With Low Likelihood of HIV Exposure: A Randomized, Double-Blind, Placebo-Controlled Study. J Infect Dis. 2026. PMID: 42770214. doi:10.1093/infdis/jiag439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。